MYGN — MYRIAD GENETICS INC
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 899923 ·
Last close
$4.20
Market Cap
$401.73M
52W High
$8.59
52W Low
$2.74
ADV30
2,033,742
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 200,400,000 | 137,600,000 | -25,300,000 | -34,100,000 | 673,700,000 | 124,400,000 | 336,300,000 |
| Dec 2025 | 209,800,000 | 146,800,000 | -3,000,000 | -7,900,000 | 706,600,000 | 149,600,000 | 338,600,000 |
| Sep 2025 | 205,700,000 | 143,800,000 | -23,300,000 | -27,400,000 | 728,100,000 | 145,400,000 | 355,300,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,400,000
Investing CF
$-25,600,000
Financing CF
$47,600,000
CapEx
$-25,600,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.19
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,156,800,000
Inventory
$27,900,000
Receivables
$123,800,000
ST Investments
$0
EBIT TTM
$-386,000,000
Pretax Income TTM
$-399,800,000
Interest Exp TTM
$13,800,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$557,000,000
EBITDA
$-111,900,000
Free Cash Flow
$-46,062,500
Enterprise Value
$176,421,792
Total Cash
$150,700,000
Total Debt
$0
Shares Out
95,649,645
Trailing EPS
$-1.18
Book Value
$3.18
ROE
-23.5%
ROA
-7.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 824,500,000 | -67,800,000 | -365,900,000 | 706,600,000 | 338,600,000 | 368,000,000 | 1,800,000 |
| Dec 2024 | 837,600,000 | -88,000,000 | -127,300,000 | 1,027,600,000 | 326,500,000 | 701,100,000 | -8,700,000 |
| Dec 2023 | 753,200,000 | -144,600,000 | -263,300,000 | 1,146,500,000 | 363,300,000 | 783,200,000 | -110,900,000 |
| Dec 2022 | 678,400,000 | -123,700,000 | -112,000,000 | 1,198,700,000 | 312,900,000 | 885,800,000 | -106,300,000 |
TTM Snapshot
Revenues TTM
$829,000,000
NetIncome TTM
$-399,900,000
OpCashFlow TTM
—
Assets (Latest)
$673,700,000
Forward EPS
$-0.57
Max Pain — expiry 2027-02-19
max pain strike: $4.00 · spot: $4.28 · call oi: 2,293 · put oi: 72
Expected Move to 2027-02-19:
±$1.73
(40.26%) —
implied range
$2.56 –
$6.01
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRC | NRC HEALTH | $451.68M | $20.42 | — |
| TKNO | Alpha Teknova, Inc. | $453.13M | $8.44 | — |
| ONMD | OneMedNet Corp | $285.76M | $4.82 | — |
| OABI | OmniAb, Inc. | $677.52M | $4.66 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $739.87M | $7.19 | — |
News headlines (Yahoo Finance, 1h cache)
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
2026-10-08 13:00 · Yahoo
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
2026-10-08 13:00 · Yahoo
Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets
2026-10-04 03:10 · Yahoo
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
2026-09-24 15:28 · Yahoo
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
2026-09-18 07:14 · Yahoo
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
2026-09-17 10:10 · Yahoo
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
2026-09-16 12:00 · Yahoo
2 Unprofitable Stocks to Research Further and 1 We Find Risky
2026-09-15 07:40 · Yahoo
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
2026-09-02 17:08 · Yahoo
Why Myriad Genetics (MYGN) Stock Is Down Today
2026-09-01 20:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.